Table 1 The patients’ characteristics at diagnosis according to myelofibrosis (n = 316)
|  | MF = 0/1 (n = 273) | MF = 2/3 (n = 43) | P |
|---|---|---|---|
Age (years), median, range | 52 (14–83) | 52 (21–79) | 0.705 |
Gender, no. (%) | |||
 Male | 181 (66.3%) | 27 (62.8%) | 0.652 |
 Female | 92 (33.7%) | 16 (37.2%) |  |
Median WBC (range), × 109/L | 2.66 (0.27–13.47) | 2.73 (1.10–12.00) | 0.609 |
Median NE (range), × 109/L | 0.99 (0.02–11.34) | 0.85 (0.04–4.92) | 0.794 |
Median HGB (range), g/L | 69 (26–150) | 67 (30–138) | 0.291 |
Median PLT (range), × 109/L | 53 (1–408) | 47 (3–282) | 0.911 |
MDS subtypes (WHO, 2016), no. (%) | 0.243 | ||
 MDS-SLD | 11 (4.0%) | 2 (4.7%) |  |
 MDS-MLD | 52 (19.1%) | 4 (9.3%) |  |
 MDS-RS-SLD | 2 (0.7%) | 2 (4.7%) |  |
 MDS-RS-MLD | 8 (2.9%) | 3 (7.0%) |  |
 MDS with isolated 5q-deletion | 2 (0.7%) | 0 (0.0%) |  |
 MDS-EB-1 | 70 (25.7%) | 10 (23.2%) |  |
 MDS-EB-2 | 118 (43.2%) | 21 (48.8%) |  |
 MDS-U | 10 (3.7%) | 1 (2.3%) |  |
Cytogenetic | 0.001 | ||
 Normal karyotype | 148 (54.2%) | 12 (27.9%) |  |
 Aberrant karyotype | 125 (45.8%) | 31 (72.1%) |  |
IPSS-R risk group, no. (%) | 0.859 | ||
 Very low | 4 (1.5%) | 0 (0.0%) |  |
 Low | 29 (10.6%) | 5 (11.6%) |  |
 Intermediate | 65 (23.8%) | 9 (20.9%) |  |
 High | 84 (30.8%) | 12 (27.9%) |  |
 Very high | 91 (33.3%) | 17 (39.6%) |  |
Treatment, no. (%) | 0.170 | ||
 Allogeneic HSCT | 121 (44.3%) | 20 (46.5%) |  |
 Cytoreductive treatments without HSCT | 90 (33.0%) | 12 (27.9%) |  |
  HMA | 68 (25.0%) | 10 (23.2%) |  |
  Chemotherapy combined with HMA | 20 (7.3%) | 2 (4.7%) |  |
  AML-like chemotherapy | 2 (0.7%) | 0 (0.0%) |  |
 Immunoregulatory | 11 (4.0%) | 5 (11.6%) |  |
 Supportive care | 51 (18.7%) | 6 (14.0%) |  |
Leukemia transformation, no. (%) | 50 (18.3%) | 8 (18.6%) | 0.964 |
Median time from diagnosis to leukemia transformation, months (range) | 12 (2–31) | 7 (1–20) | 0.043 |